iDD Research Solutions Imbibing Technology-Driven Cr Solutions Endeavouring To Build A Favouring Healthcare Ecosystem

iDD Research Solutions Imbibing Technology-Driven Cr Solutions Endeavouring To Build A Favouring Healthcare Ecosystem

D.T. Arasu,Managing Director

D.T. Arasu

Managing Director

Weighed by the latest stats and information of several chronic diseases (including COVID-19) as the healthcare today conscientiously shifts towards patient-centric applied services worldwide, clinical trials lays a great deal amidst the clinical research industry. Fuelled by the demand, the global clinical trials market which was valued at $46.8 billion in 2019 is now expected to grow at a CAGR of 5.1 percent during 2020 to 2027. For representing this high stake extravagant industry, today thousands of clinical research organizations have emerged in the space and are striving to deploy desired clinical trials results for medicine and medical devices. Outperforming a bulk of organizations predicating unsolicited clinical trial results, Hyderabad-based iDD Research Solutions INC (formerly i5 Clinical Research) incises its competition by providing full-service clinical research specialized in early clinical development and integrated proof of concept (PoC) packages. Evolved as a full-fledged CRO, iDD holds an unparalleled experience of managing hundreds of studies as a SDMO and as a CRO.

Founded in 2009 under the aegis of D.T. Arasu (Founder & MD), iDD Research Solutions is the one that can be sweared on for best quality clinical research entities and on-time service that too at most economic cost. Adhering to all the global regulatory standards (including ICH-GCP, ICMR, EMEA and FDA standards), this independent CRO offers clinical research solutions to its clients in the Pharmaceutical, Neutraceutical, Biotechnology and Medical Device industry, and further supports them in the conduct of clinical trials, which includes Pilot Studies, Pivotal Studies, Phase Studies and Therapeutic Equivalence studies, right from designing the study till reporting the same. Looking out to explore more about iDD’s contributions and propositions, CEO Insights indulges in a conversation with D.T. Arasu. Here are the excerpts:

Spearheading such a recognized CRO, iDD you have already crossed over a decade. How far have your educational and professional
background been instrumental in the inception of iDD Research Solutions?
Indeed, it has been a glorious journey! I am a B.Sc. in Mibrobiology, and have completed Masters in Biotechnology, followed MBA in Marketing & Six Sigma. To begin with, I first started off working as a sales boy (Home Applinaces) in my college time (summer holidays). Later, I ventured into clinical research (CR) industry in 2005. However, my entrepreneurial journey kicked-off with i5(now iDD) in the year, when I was 25 and it’s been 12 years now. Also, within this tenure I ventured into seven entities (different industries) with few flops. Most of this actually happened betwixt 2013-2018, during the lag phase of clinical trial industry.

However, readjusting my focus on CR (my core filed), I revamped i5 as iDD with head office in Minnesota, US in 2018. But the learning I had from real life experiences and fellow human beings has been the biggest erudition, I would say. With respect to professional experience, I have been fortunate to work with two great organizations like Apollo Hospitals (under Dr. Araham Oomman) and Synchron Research (Dr. Shiv in Synchron), Ahmedabad. Those are the real foundation which is backing me to run the show now.

How is iDD Research Solutions creating a niche in clinical search segment through its cutting edge solutions?
Known for its client retention rates, iDD, a DIA member is a visionary that firmly cynosures on collaborative model of work to achieve real time goals. As says, our slogan, ‘It’s our approach and intentions which differentiate us from others’, we make it happen by collating right brains with required experience for the targeted projects.

We have always maintained the right mix of new vs experienced candidates, and thereby we are proud to say that in last 12 years iDD has been a launch pad for 100s of fresh talents into the CR industry. Our resourcing model and training strategy help us being competitive in costing as well. However, going forward the differentiator for iDD is going to be our iTRIALs concept with our flagship product iSMART TM, which will make iDD a first fully integrated Digital CRO. iTRIALs concept is built with three key principles - Integrate, Innovate and Improvise.

Mention the challenges that accompanied iDD’s clinical trials. How did you mitigate those? Also, further what are your strategies to make the most of this burgeoning CR industry?
One of the key challenges any clinical trial faces globally is completing the study within the planned time and budget, due to by
many key contributors like recruitment & retention, quality of data, deviation rate, site compliance to process and resource stability at sites & CRO. iDD’s iTRIALs concept is built with appropriate automation and real time data access to address most of the above mentioned issues at the right time. Most importantly, to avoid certain errors through our (to be patented) technology ‘AI check’, (a next generation edit check technology) we can almost eradicate the data entry error and qualify data at entry level, thus saving time and cost.

iSMART TM, the first product in our iTRIALs concept which will be launched by Jan 2021, is expected to have an impact on overall trial in all stages. Also, for patients we have a tool named iPET, it’s a cloudbased solution to revolutionize feasibility, study conduct and patient enrollment. i-PET facilitates global connectivity to achieve fastest ever feasibility survey/study across the globe, and it enhances site performance with respect to recruitment by cross references and its unique patient enrollment process. These are the ways, we have integrated lots of innovative technologies in right way to bring everything on one single platform.

What is the blueprint mapped for iDD?
The current COVID-19 pandemic situation has definitely led to the booming of CR industry, drawing increased awareness towards the need for evidence-based (data) healthcare, manifolds. Henceforth, currently we are also working for around five clients in eight studies for COVID alone, ranging from Allopathic to traditional medicine, including health-tech devices. As far as iDD’s business is concerned, from the operational perspective we have seen 3x growth in the first two quarters of 2020 and expect to close with minimum 4x growth this year, in comparison to 2019. Conclusively, we want to keep working towards creating a more favouring environment for healthcare & society.

D.T. Arasu, Managing Director
An optimistic leader & entrepreneur, D.T. Arasu is a B.Sc. Microbiology, Masters in Biotechnology, and also holds M.B.A in Marketing & Six Sigma. Having worked with some recognized organizations like Apollo Hospitals and Synchron Research, Ahmedabad, he is channelizing his experience towards creating an exemplary ecosystem for healthcare & society through iDD Research Solutions, a full-fledged CRO.

Other Directors: Dr. Yogesh Sharma, Co-Founder & Medical Director, Karkavel, Co-Founder & CTO, Ravi Rangasami, Co-Founder & Legal & Finance Director Patrick Benson, Co-Founder & Business Head.
Location: Hyderabad

Trending Stories